Search results for "Induction"

showing 10 items of 769 documents

Influence of gallic acid esters on drug-metabolizing enzymes of rat liver

1982

The effect of three antioxidants, propyl, octyl and dodecyl gallate, on hepatic drug metabolism in male rats was studied in vivo and in vitro. When fed at a dietary concentration of 1% for 14 days, only dodecyl gallate increased relative liver weight. Cytochrome P-450 content was not influenced, but a slight increase in cytochrome b5 content was observed after the feeding of propyl gallate. Monooxygenase activity (benzo[a]pyrene-hydroxylase and ethoxycoumarin-deethylase activities) was not affected by propyl or octyl gallate, but a significant decrease in benzo[a]pyrene-hydroxylase activity was apparent in rats fed dodecyl gallate. Study of benzo[a]pyrene-metabolite formation in liver micro…

MaleMetabolitePharmacologyToxicologyAntioxidantsMixed Function Oxygenaseschemistry.chemical_compoundCytochrome P-450 Enzyme SystemGallic Acidpolycyclic compoundsAnimalsGallic acidBenzopyrene HydroxylasePropyl gallateEstersRats Inbred StrainsDodecyl gallateGeneral MedicineGallateCytochrome b GroupDietRatsCytochromes b5chemistryBiochemistryEnzyme InductionMicrosomes LiverMicrosomeOctyl gallateDrug metabolismFood ScienceFood and Chemical Toxicology
researchProduct

Induction of brain CYP2E1 changes the effects of ethanol on dopamine release in nucleus accumbens shell.

2009

CYP2E1 is an important enzyme involved in the brain metabolism of ethanol that can be induced by chronic consumption of alcohol. Recent works have highlighted the importance of this system in the context of the behavioural effects of ethanol. Unfortunately, the underlying neurochemical events for these behavioural changes, has not been yet explored. In this work, we have started this exploration by analyzing the possible changes in the neurochemical response of the mesolimbic system to ethanol after pharmacological induction of brain CYP2E1. We have used the dopamine extracellular levels in nucleus accumbens (NAc) core and shell, measured by means of microdialysis in vivo, as an index of th…

MaleMicrodialysisDopamineContext (language use)Nucleus accumbensPharmacologyToxicologyNucleus Accumbenschemistry.chemical_compoundNeurochemicalDopaminemedicineAnimalsPharmacology (medical)Rats WistarNeurotransmitterInfusions IntravenousPharmacologyEthanolEthanolBrainCytochrome P-450 CYP2E1RatsPsychiatry and Mental healthchemistryEnzyme InductionCatecholamineNeurosciencemedicine.drugDrug and alcohol dependence
researchProduct

Anticonvulsants do not suppress long-term potentiation (LTP) in the rat hippocampus

1991

Long-term potentiation (LTP) of population spikes in the CA1 area of rat hippocampus was induced by tetanic stimulation of stratum radiatum in slices kept submerged in a perfusion chamber. Addition of the two antiepileptic drugs phenytoin or the diazepine midazolam to the medium did not significantly alter this phenomenon within 22 min after the tetanus. The early enhancement (post-tetanic potentiation, PTP) was reduced only by phenytoin. Therefore an interaction of these drugs with N-methyl-D-aspartate (NMDA) receptors and LTP induction is unlikely.

MaleMidazolammedicine.medical_treatmentPopulationHippocampusIn Vitro TechniquesPharmacologyNeurotransmissionHippocampusLTP inductionmedicineAnimalseducationEvoked Potentialsgamma-Aminobutyric Acideducation.field_of_studyChemistryGeneral NeuroscienceRats Inbred StrainsLong-term potentiationRatsAnticonvulsantnervous systemPhenytoinSynapsesNMDA receptorAnticonvulsantsFemaleTetanic stimulationNeuroscience Letters
researchProduct

Differential modulation of CYP2E1 activity by cAMP-dependent protein kinase upon Ser129 replacement.

1998

Many toxic compounds are activated by cytochrome P450 (CYP) 2E1 to reactive metabolites, which represents a potential hazard for cellular homeostasis. Therefore knowledge about CYP2E1 regulation could be of great biological importance. It has been shown that CYP2E1 is controlled transcriptionally and post-translationally by phosphorylation. In the present study we investigated the role of serine-129 (Ser129) in the protein kinase A (PKA) recognition sequence motif Arg-Arg-Phe-Ser129. To gain further insights into the possible relevance of Ser129 for CYP2E1 function, Ser129 was replaced by alanine (Ala) or glycine (Gly) by site-directed mutations of the cDNA coding for CYP2E1. The mutant cDN…

MaleMutantCellular homeostasisTransfectionDimethylnitrosamineSubstrate SpecificityRats Sprague-DawleyMiceCricetulusCricetinaeIsoniazidSerineAnimalsEnzyme inducerPhosphorylationProtein kinase ALungCells Culturedchemistry.chemical_classificationMice Inbred BALB CbiologyCytochrome P-450 CYP2E1Cell BiologyFibroblastsMolecular biologyCyclic AMP-Dependent Protein KinasesAmino acidRatsEnzymechemistryBiochemistryAmino Acid SubstitutionBucladesineEnzyme InductionInactivation MetabolicMutationbiology.proteinMicrosomes LiverPhosphorylationDemethylaseMutagensExperimental cell research
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

MaleOncogene Proteins Fusionmedicine.medical_treatmentDrug ResistancePhases of clinical researchSalvage therapyKaplan-Meier EstimatePharmacologyGastroenterologyBenzoatesArsenicalschemistry.chemical_compoundLeukemia Promyelocytic AcuteRecurrenceAntineoplastic Combined Chemotherapy ProtocolsMedicineArsenic trioxidePromyelocyticOncogene ProteinsTumorLeukemiaRemission InductionHematopoietic Stem Cell TransplantationCell DifferentiationOxidesclinical trialHematologyMiddle AgedCombined Modality Therapyall-trans retinoic acidarsenic trioxideLeukemiaCardiovascular DiseasesFemalemedicine.drugAdultmedicine.medical_specialtyTetrahydronaphthalenesAcute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; clinical trial; tamibarotene; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia Promyelocytic Acute; Male; Middle Aged; Oncogene Proteins Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; TretinoinAntineoplastic AgentsTretinoinAcuteArticleDisease-Free SurvivalTretinoinInternal medicineBiomarkers TumorHumansFusionneoplasmsAgedFebrile NeutropeniaSalvage TherapyChemotherapybusiness.industrymedicine.diseasetamibaroteneAcute promyelocytic leukaemiaConsolidation ChemotherapychemistryDrug Resistance NeoplasmNeoplasmTamibarotenebusinessSettore MED/15 - Malattie del SangueFebrile neutropeniaBiomarkers
researchProduct

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters

2016

Purpose To assess an intensified treatment in the context of clinical and biologic risk factors in metastatic medulloblastoma. Patients and Methods Patients (4 to 21 years old, diagnosed between 2001 and 2007) received induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy. Subgroup status and other biologic parameters were assessed. Results In 123 eligible patients (median age, 8.2 years old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were 62% (95% CI, 52 to 72) and 74% (95% CI, 66 to 82), respectively. OS was superior compared with the precedent HIT ’91 trial. The 5-year EFS and OS wer…

MaleOncologyCancer Researchmedicine.medical_specialtyAdolescentPopulationMedizinMaintenance ChemotherapyAnaplastic MedulloblastomaYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineProspective StudiesNeoplasm MetastasisCerebellar NeoplasmsChildeducationSurvival rateMedulloblastomaeducation.field_of_studybusiness.industryHazard ratioInduction chemotherapyPrognosismedicine.diseaseCombined Modality TherapySurgerySurvival RateRegimenExact testOncologyAustriaChild Preschool030220 oncology & carcinogenesisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessSwitzerland030217 neurology & neurosurgeryMedulloblastomaJournal of Clinical Oncology
researchProduct

A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung can…

2007

The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients has not been defined to date. The present phase II study was planned to evaluate the activity and safety of platinum-based induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Patients received two cycles of paclitaxel (175 mg/m) and carboplatin (area under the curve: 5) day 1, every 3 weeks. Chemoradiotherapy (thoracic radiation therapy) was initiated on day 42 and consisted of 1.8 Gy daily, five times per week over 5 weeks (45.0 Gy target dose) followed by 10 2.0 Gy daily fractions. Concomitant chemotherapy wa…

MaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsSettore MED/06 - Oncologia MedicaLocally advancedPhases of clinical researchDisease-Free SurvivalDrug Administration ScheduleOlder patientsCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerAgedNeoplasm StagingPharmacologybusiness.industryInduction chemotherapymedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOptimal managementConcurrent chemoradiotherapynon-small-cell lung cancerchemoradiotherapyOncologyFemaleNon small cellbusiness
researchProduct

Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial

2008

Purpose Adjuvant 5-fluorouracil–based chemoradiotherapy has been shown to improve the prognosis of gastric cancer. To optimize these results, in the present study oxaliplatin and capecitabine were used instead of 5-fluorouracil. We sought to determine the maximum tolerated dose and the dose-limiting toxicities (DLT) of these drugs in combination with intensity-modulated radiotherapy. Methods and Materials Patients with resected adenocarcinoma of the stomach or the gastroesophageal junction were included. They received two cycles of induction chemotherapy (oxaliplatin and capecitabine [XelOx] regimen). Using standard Phase I methodology, patients received 45 Gy in 1.8-Gy fractions either in …

MaleOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsNauseamedicine.medical_treatmentDeoxycytidineGastroenterologyCapecitabineLeukocytopeniaStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingCapecitabineAgedChemotherapyRadiationbusiness.industryInduction chemotherapyMiddle AgedCombined Modality TherapyOxaliplatinOxaliplatinRegimenOncologyFemaleRadiotherapy AdjuvantFluorouracilmedicine.symptombusinessChemoradiotherapymedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy

2008

To investigate the utility of postoperative chemotherapy in delaying radiotherapy and to identify prognostic factors in early childhood medulloblastoma, we studied children younger than 3 years of age registered to the HIT-SKK'87 (Therapieprotokoll für Säuglinge und Kleinkinder mit Hirntumoren [Brain Tumor Radiotherapy for Infants and Toddlers with Medulloblastoma] 1987) trial who received systemic interval chemotherapy until craniospinal radiotherapy was applied at 3 years of age or at relapse, from 1987 to 1993. Children with postoperative residual tumor or metastatic disease received systemic induction chemotherapy prior to interval chemotherapy. Twenty-nine children were eligible for an…

MaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentClinical InvestigationsBrain tumorAntineoplastic AgentsPilot ProjectsDisease-Free SurvivalInternal medicineHumansMedicineProgression-free survivalCerebellar NeoplasmsSurvival rateMedulloblastomaChemotherapybusiness.industryInfantInduction chemotherapyPrognosismedicine.diseaseCombined Modality TherapyChemotherapy regimenSurgerySurvival RateRadiation therapyTreatment OutcomeOncologyChild PreschoolFemaleNeurology (clinical)Cranial IrradiationNeoplasm Recurrence LocalbusinessMedulloblastomaNeuro-Oncology
researchProduct